-
Detailed Analysis Generate Full Report Add to Watchlist
Values as of: 2019-07-15
Values as of: 2019-07-15
The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Pharmaceutical IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of pharmaceutical companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 23 U.S. pharmaceuticals companies. These companies are engaged principally in the research, development, manufacture, sale or distribution of pharmaceuticals and drugs of all types. The fund is non-diversified.
Company Website : www.invescopowershares.com
Currency: USD
Country : USA
Inception Date: 23/06/2005
Primary Benchmark: Dynamic Pharmaceutical Intellidex TR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.57%
Management Expense Ratio: 0.56 %
N/A
N/A
N/A
N/A
| Symbol | Name | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|
| SOJE | SOJE | 0.00 % |
+0.04 (+0.21%) |
USD 65.72B |
| JEPI | JPMorgan Equity Premium Income.. | 0.00 % |
-0.11 (-0.20%) |
USD 32.78B |
| LCR | Leuthold Core ETF | 0.00 % |
-0.09 (-0.27%) |
USD 32.52B |
| DTB | DTB | 0.00 % |
-0.12 (-0.63%) |
USD 26.58B |
| DFAC | Dimensional U.S. Core Equity 2.. | 0.00 % |
-0.03 (-0.10%) |
USD 26.11B |
| JPST | JPMorgan Ultra-Short Income ET.. | 0.00 % |
N/A |
USD 22.47B |
| SGOV | iShares® 0-3 Month Treasury B.. | 0.00 % |
+0.03 (+0.03%) |
USD 18.58B |
| TSPA | T. Rowe Price US Equity Resear.. | 0.00 % |
-0.07 (-0.22%) |
USD 16.23B |
| DFUV | Dimensional US Marketwide Valu.. | 0.00 % |
+0.04 (+0.10%) |
USD 10.15B |
| AVUV | Avantis® U.S. Small Cap Value.. | 0.00 % |
+0.02 (+0.02%) |
USD 10.05B |
N/A
| Market Performance vs. Industry/Classification (Others) | Market Performance vs. Exchange (NYSE Arca) | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | -6.11% | 7% | C- | 12% | F | ||
| Dividend Return | 0.30% | 6% | D- | 4% | F | ||
| Total Return | -5.81% | 7% | C- | 12% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | -16.98% | 8% | B- | 21% | F | ||
| Dividend Return | 0.49% | 9% | A- | 6% | D- | ||
| Total Return | -16.48% | 7% | C- | 19% | F | ||
| Trailing 5 Years | |||||||
| Capital Gain | -3.81% | 38% | F | 44% | F | ||
| Dividend Return | 5.74% | 27% | F | 20% | F | ||
| Total Return | 1.93% | 32% | F | 34% | F | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 0.06% | 25% | F | 42% | F | ||
| Dividend Return | 1.16% | 11% | F | 38% | F | ||
| Total Return | 1.10% | 52% | F | 29% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 13.65% | 39% | F | 78% | C+ | ||
| Risk Adjusted Return | 8.50% | 11% | F | 39% | F | ||
| Market Capitalization | 0.91B | 68% | D+ | 40% | F | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
The company had positive total cash flow in the most recent four quarters.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
